Latest news with #Cambridge
CTV News
2 hours ago
- Sport
- CTV News
Accessible upgrades to Cambridge baseball diamond hit funding challenge
City of Cambridge councillors are considering stepping up to the plate after the city did not receive funding they were hoping to use for accessibility upgrades at a baseball diamond. Last fall, council approved a plan for a series of improvements to the Kin 1 diamond at Riverside Park, which is used by a growing adaptive baseball program that's been advocating for change. Rory Small is one of the athletes that plays in Buddy League. 'I get to go in the outfield and play with my friends,' he tells CTV News. Rory is one of more than 115 participants in Buddy League this year. However, some of those athletes find even just getting to the diamond a challenge. 'A lot of athletes do come here in their wheelchairs,' says Monica Small, Rory's mother. 'There is not a clear path, it's actually gravel. And so a lot of the wheelchairs will get stuck.' Buddy League Cambridge Kin 1 diamond Mother Monica Small and her son, and Buddy League athlete, Rory Small, posed for a photo on July 22, 2025. (Krista Simpson/CTV News) The space also lacks accessible washrooms, the infield can be difficult to navigate and the dugouts are narrow. Last fall, Cambridge council voted to move ahead with a list of upgrades including pathways, better bleachers, an artificial turf infield, accessible dugouts and accessible washrooms. 'Making sure that it is fully accessible and fully inclusive is really, really valuable and really most important for ensuring that everybody can get off the sidelines and into the game,' Cam Linwood, league co-ordinator for Buddy League, said. The promised upgrades come at an estimated cost of $3,025,000. The city had hoped about half of that cost would be covered through grants and donations. However, the city's application to the Jays Care Foundation was unsuccessful. City staff are now recommending the entire amount be funded through debt, in hopes of keeping the timeline on track, even as they continue to explore other sources of donations. 'It is an investment within the community and within the people that live here,' Small said. Linwood added that the changes will benefit the community as a whole. 'This is really that chance to be that welcoming space. Not only is it a facility that we can use as Buddy League, but the entire community can use.' Kin 1 diamond at Riverside Park Kin 1 diamond at Riverside Park was photographed on July 22, 2025. (Krista Simpson/CTV News) Linwood noted that the project is largely inspired by an accessible diamond in Antigonish, Nova Scotia, that is used by all players, and not just those with disabilities. The city of Cambridge has also launched a fundraising campaign encouraging private donations from residents, groups and businesses. Small urged anyone interested in donating to come and see what Buddy League is all about. 'Hang out with us. Just spend some time with us. I'm telling you, you'll fall in love with the sport. You're going to fall in love with the athletes, and you're going to fall in love with this community. 'Work to make the washrooms accessible is expected to start soon. Field improvements could begin after the end of this baseball season and be finished by summer 2026.
CBC
6 hours ago
- CBC
Inert grenade found after alleged bike thief stopped on University of Waterloo campus
Police have recovered an inert grenade after a man allegedly riding a stolen bicycle was stopped on the University of Waterloo (UW) campus on Tuesday morning. Police were called to the school around 6 a.m. after members of UW's Special Constable Service saw a man riding a bike on campus that had been reported stolen. The inert grenade was found when the constables were arresting the man, police said. According to Waterloo Regional Police Service (WRPS), an inert grenade is empty and doesn't contain explosive material. It can mimic a live grenade by producing a popping sound and it is used during training and demonstration purposes. When WRPS arrived on scene, the university sent a notice via texts and on their website to staff and students informing them that police were on campus for an active investigation. "The campus remains open," the notice had read in part. "If you're on campus, follow instructions from the authorities." Once police completed their investigation, they determined there were no public safety concerns. Staff and students were updated through UW's notification system letting them know that "the campus remains open for normal activities following the investigation." Police have charged a 36-year-old man from Cambridge with: Possession of stolen goods under $5,000 (two counts). Possession of identity documents. Possession of break and enter tools. Anyone with information is being asked to call police.
CTV News
7 hours ago
- CTV News
Bike theft leads police to inert grenade at the University of Waterloo
The University of Waterloo on July 22, 2025. (Hannah Schmidt/CTV News) Waterloo Regional Police say an inert grenade was found on an alleged bike thief at the University of Waterloo. Early Tuesday morning, University of Waterloo Special Constables spotted a man riding a bicycle on campus. That same bike had been reported stolen. The Special Constables arrested the man. During a subsequent search, they realized the man was carrying an inert grenade. Waterloo Regional Police said their officers were called to the campus around 6 a.m. and determined there were no public safety concerns. The 36-year-old Cambridge man was charged with two counts of possessing stolen goods under $5,000, possession of identity documents and possession of break and enter tools.
Yahoo
7 hours ago
- Business
- Yahoo
Former Sandoz Inc. CEO Don DeGolyer Leads PharmaTech Startup Ategenos as Company Prepares Public Launch
Veteran pharma operator co-founded Ategenos to tackle the global $1 trillion crisis of medication non-adherence CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ -- Ategenos, a pharmatech company, today announced that Co-Founder and Chief Executive Officer Don DeGolyer is leading the company as it prepares to exit stealth and unveil its platform addressing one of healthcare's most costly and persistent challenges: medication non-adherence. Logo of Ategenos, a PharmaTech company focused on connected drug delivery Ategenos has been quietly developing a novel platform that integrates pharmaceutical science with real-time digital health technologies to address adherence in critical dose management. The company will share details on its SmartPatch platform and initial partnerships in the coming weeks. "Medication doesn't work if it's not taken. Yet non-adherence remains one of the biggest drivers of avoidable healthcare costs worldwide," said DeGolyer. "From the start, we set out to build a platform that combines drug delivery, actionable real-world data, and caregiver intervention. We provide caregivers the peace of mind that their loved ones have taken their critical dose medicines and are not at risk of a catastrophic health event." Medication non-adherence contributes to an estimated 125,000 preventable deaths and more than $500 billion in avoidable healthcare costs annually in the U.S., with global costs exceeding $1 trillion each year. DeGolyer brings over 40 years of leadership across the pharmaceutical industry. As President & CEO of Sandoz Inc., he grew revenues by $2 billion in four years, building one of the largest generics businesses in North America. As COO of Endo Pharmaceuticals, he helped scale the company from $2 billion to $18 billion in market cap within two years. He also founded and led Vertice Pharmaceuticals, doubling revenue during his tenure and building a platform that later contributed to a $700 million strategic sale. Don has held senior roles at Pfizer, Johnson & Johnson, and Novartis, advisory positions with Koch Investment Group and Formation Bio, and serves on the board of Emergent BioSolutions. DeGolyer has built a founding team combining pharma leadership, MIT-rooted technology innovation, and venture capital expertise. With experience spanning drug delivery, IoT, real-world data, and company building, Ategenos is uniquely positioned to operate at the intersection of pharmaceuticals and technology. About Ategenos Ategenos is a Massachusetts-based PharmaTech company improving quality of life for patients and their families with its SmartPatch platform—an advanced transdermal system that combines sustained drug delivery with real-time monitoring and caregiver interventions. The technology reduces health risks, hospitalizations, and the $1T+ global costs caused by missed doses of critical medications. The company's founders uniquely combine global pharma leadership, MIT-driven technology, and a proven track record of building and scaling healthcare platforms.
Associated Press
7 hours ago
- Business
- Associated Press
Former Sandoz Inc. CEO Don DeGolyer Leads PharmaTech Startup Ategenos as Company Prepares Public Launch
Veteran pharma operator co-founded Ategenos to tackle the global $1 trillion crisis of medication non-adherence CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ -- Ategenos, a pharmatech company, today announced that Co-Founder and Chief Executive Officer Don DeGolyer is leading the company as it prepares to exit stealth and unveil its platform addressing one of healthcare's most costly and persistent challenges: medication non-adherence. Ategenos has been quietly developing a novel platform that integrates pharmaceutical science with real-time digital health technologies to address adherence in critical dose management. The company will share details on its SmartPatch platform and initial partnerships in the coming weeks. 'Medication doesn't work if it's not taken. Yet non-adherence remains one of the biggest drivers of avoidable healthcare costs worldwide,' said DeGolyer. 'From the start, we set out to build a platform that combines drug delivery, actionable real-world data, and caregiver intervention. We provide caregivers the peace of mind that their loved ones have taken their critical dose medicines and are not at risk of a catastrophic health event.' Medication non-adherence contributes to an estimated 125,000 preventable deaths and more than $500 billion in avoidable healthcare costs annually in the U.S., with global costs exceeding $1 trillion each year. DeGolyer brings over 40 years of leadership across the pharmaceutical industry. As President & CEO of Sandoz Inc., he grew revenues by $2 billion in four years, building one of the largest generics businesses in North America. As COO of Endo Pharmaceuticals, he helped scale the company from $2 billion to $18 billion in market cap within two years. He also founded and led Vertice Pharmaceuticals, doubling revenue during his tenure and building a platform that later contributed to a $700 million strategic sale. Don has held senior roles at Pfizer, Johnson & Johnson, and Novartis, advisory positions with Koch Investment Group and Formation Bio, and serves on the board of Emergent BioSolutions. DeGolyer has built a founding team combining pharma leadership, MIT-rooted technology innovation, and venture capital expertise. With experience spanning drug delivery, IoT, real-world data, and company building, Ategenos is uniquely positioned to operate at the intersection of pharmaceuticals and technology. About Ategenos Ategenos is a Massachusetts-based PharmaTech company improving quality of life for patients and their families with its SmartPatch platform—an advanced transdermal system that combines sustained drug delivery with real-time monitoring and caregiver interventions. The technology reduces health risks, hospitalizations, and the $1T+ global costs caused by missed doses of critical medications. The company's founders uniquely combine global pharma leadership, MIT-driven technology, and a proven track record of building and scaling healthcare platforms. For Media Inquiries: [email protected] For Strategic Partnerships: [email protected] For Investment Opportunities: [email protected] View original content to download multimedia: SOURCE Ategenos Pharmaceuticals Inc.
